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Abstract
The frequencies of alleles and genotypes of TNF-α, TNF-β, and IL-10 genes were exam-
ined in Saudi subjects including IBD patients (UC and CD) and matched controls.
Venous blood samples were collected from IBD patients and healthy control subjects,
and genomic DNA was extracted using commercially available kit (Qiagen, CA, USA).
In order to detect TNF-α (-308G/A), TNF-β (+252A/G), IL-10 (-1082G/A), (-819C/T), and
(-592C/A) polymorphisms, the TNF-α, TNF-β, and IL-10 genes were amplified using an
amplification refractory mutation systems PCR methodology. Analysis of data showed
that the frequencies of alleles and genotype of TNF-α (-308G/A), TNF-β (+252A/G), and
IL-10 (-1082G/A), (-819C/T), and (-592C/A) polymorphisms differ between IBD patients
and control subjects. Our study clearly indicated that the TNF-α (-308G/A), TNF-β
(+252A/G), and IL-10 (-1082 G/A) polymorphisms are associated significantly with the
risk of IBD susceptibility while other two, IL-10-819C/T and IL-10-592C/A, polymor-
phisms are not associated with IBD in Saudi population. However, well-designed epi-
demiological as well as genetic association studies with large sample size among
different ethnicities should be performed in order to have better understanding of this
relationship.
Keywords: tumor necrosis factor, interleukin-10, polymorphism, inflammatory bowel
disease, Saudis, Crohn’s disease, ulcerative colitis
1. Introduction
The inflammatory bowel diseases (IBDs), encompassing Crohn’s disease (CD, OMIM 266600)
and ulcerative colitis (UC, OMIM 191390), are chronic inflammatory disorders of the gastro-
intestinal tract. The incidence and prevalence of IBD have been increasing with time in
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different regions around the world, indicating its emergence as a global disease [1–5]. Avail-
able literature indicates that IBD is a complex and multifactorial disease though the exact
etiology is still not clear. However, it has been suggested that immune dysregulation caused
by genetic and/or environmental factors plays an important role in the etiology of IBD [6–8].
IBD appears to be caused by overly aggressive T-cell responses directed against environmental
factors and/or a subset of commensal bacteria/pathogens that inhabit the distal ileum and
colon of genetically susceptible hosts. Patients with long-lasting IBD, both UC and CD, have
been at increased risk of developing colorectal cancer, and CD patients are at increased risk of
small intestine cancer [9].
The incidence of IBD is higher in North American and European populations compared with
those in Asian and African, reflecting the role of both environmental and genetic factors. The
rising prevalence of various autoimmune and inflammatory conditions in developed countries
has been attributed to hygiene hypothesis, and they are thought to result from the lack of early
exposure to select microbial agents due to stringent sanitation conditions [10]. The changes in
dietary and intestinal microbial milieu have been suggested to play a key pathogenic role in
the etiology of IBD, though the exact environmental factors responsible for changing IBD
prevalence are not clearly defined [11]. Intriguingly, the characteristics of Western and Asian
IBD patients differ in epidemiology, phenotype, and genetic susceptibility [12–15] highlighting
ethnic variations. Various epidemiological and population-based studies have indicated that
genetic factors contribute to the pathogenesis of IBD [16–18].
According to Jump and Levine [19], cytokines act as key signal in the intestinal immune
system and participate in the disruption of the physiological inflammation of the gut. They
are produced mainly by immune cells as small peptide proteins and facilitate communication
between cells, by stimulating the proliferation of antigen-specific effector cells, and mediate
the local and systemic inflammation in an autocrine, paracrine, and endocrine pathways [20].
A critical role is played by innate immune system in IBD pathology, and several cytokines
secreted by activated dendritic cells (DC) and macrophages actively regulate the inflammatory
response in IBD.
The production of cytokines can be affected by genetic polymorphisms within the coding and
promoter regions of cytokine genes [21, 22]. Therefore, a genetic predisposition for the high or low
production of a particular cytokine may affect disease susceptibility and clinical outcome [23, 24].
The IBD is believed to be caused by immunogenic responses against environmental factors
and/or microbes inhabiting distal ileum and colon of genetically susceptible hosts. Inflamma-
tory response in IBD is an important feature and proinflammatory cytokine; tumor necrosis
factor-alpha (TNF) has been indicated to play a key role in the initiation and propagation of
IBD. Increased expressions of TNF-α have been reported in peripheral phagocytes and
intestinal tissues of IBD patients. High levels of TNF-α have also been documented in the
serum of IBD patients [25–27]. Moreover, monoclonal antibodies against TNF-α have been
effectively used to decrease inflammation in IBD [28]. Variations in levels/expression of TNF
due to its genetic polymorphism have been linked with pathogenic role of this cytokine in
various autoimmune and inflammatory diseases and thus have been regarded to be an
appropriate target for management of diseases by interfering with the inflammatory
responses.
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In view of the important immunoregulatory roles of TNF-α and TNF-β, they are considered
as subject of interest for studies in IBD. TNF-α is produced mainly by monocytes and
activated macrophages while TNF-β is produced mainly by activated T cells. Both TNF-α
(OMIM 191160) and TNF-β (MIM153440) genes are located on chromosome 6 within the
MHC III region and show close linkage to the HLA class I (HLA-B) and class II (HLA-DR)
genes. It has been shown by various studies on monozygotic twins and first-degree relatives
that 60% of variation in the production capacity of TNF-α is genetically determined [29]. A
number of polymorphisms within the promoter region of TNF-α and the intron 1 polymor-
phism of TNF-β, in particular have been associated with variations in the serum levels of
TNF-α [30, 31] One of the best described single nucleotide polymorphisms (SNPs) is located
at nucleotide position -308 within the TNF-α promoter region (rs1800629) and affects a
consensus sequence for a binding site of transcription factor AP-2 [32]. TNF-α (-308) pro-
moter polymorphism leads to a less common allele-A (allele 2), which has been associated
with increased TNF-α production in vitro [33, 34] and higher rate of TNF-α transcription
than wild-type GG genotype [35, 36]. This polymorphism has been linked to increased
susceptibility to several chronic metabolic degenerative, inflammatory and autoimmune
diseases [37–41].
Of interest, G/A polymorphism at nucleotide position -308 within the human TNF-α promoter
region is associated with elevated TNF levels, disease susceptibility, and poor prognosis in
several diseases [42–45]. Adenine at position -308 makes the TNF-α promoter a much more
powerful transcription activator than guanine [42].
TNF-β +252A/G (rs909253) polymorphism affects a phorbol ester-responsive element. The
presence of G at +252 position refers to the less frequent mutant allele known as TNF-β * 1
(allele-1), which is associated with higher TNF-α and TNF-β production [42, 46].
TNF-β resembles to TNF-α in terms of several biological activities including apoptosis and
gives rise to a similar proinflammatory response and has been shown to play a critical role in
pathogenesis of many diseases. TNF-β has also been shown to contribute to the susceptibility
of several inflammatory/autoimmune diseases. Association of TNF-β +252 A/G polymorphism
has been reported with various autoimmune disorders including Gravis’ disease [47] idio-
pathic membranous glomerulonephritis, IgA nephropathy, insulin-dependent diabetes
mellitus [48], myasthenia gravis [49], asthma diathesis [50], SLE with nephritis [51], systemic
sclerosis [52], plaque psoriasis [53], rheumatoid arthritis [54], and type 1 diabetes [55].
Recently, TNF-β +252 A/G polymorphism is reported to be associated with both susceptibility
to and mortality from sepsis [56].
A few studies have been undertaken to determine the association of TNF-α polymorphisms
and IBD in different parts of the world [57–59]. The results of these studies on association of
TNF-α polymorphism with IBD are not consistent, and variations have been reported [60].
These variations might be due to genetic differences in populations or systemic variations in
the ancestry of IBD patients and control subjects involved in the studies [27]. Moreover,
differences have been found in the characteristics, epidemiology, phenotype, and genetic
susceptibility to IBD in Western and Asian populations [15, 16]. Therefore, studies involving
these unique features in different ethnic populations will help not only identifying the patho-
physiology but also understanding the etiology of IBD.
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No research has been done on the association between TNF-β polymorphism and IBD. TNF-α
and TNF-β are closely related cytokines, and both are involved in the expression of TNF-α and
in a suggested mechanism for autoimmune/inflammatory diseases; therefore, the joint analysis
of polymorphisms in TNF-α and TNF-β genes will provide further insight into the pathogene-
sis of IBD and help in developing effective therapeutic agents. Saudi population is ideal for
such genetic association studies because of the fact that it is a closed and isolated society with
quite high rate of consanguinity. So, we studied and evaluated the possible association of
alleles and genotypes of TNF-α (-308G/A) and TNF-β (+252A/G) polymorphisms with the
susceptibility risk to IBD in this population.
On the other hand, interleukin-10 (IL-10) is an anti-inflammatory cytokine and can inhibit the
synthesis of proinflammatory cytokines, such as interferon-γ, IL-2, IL-3, and tumor necrosis
factor-α (TNF-α), produced by macrophages and regulatory T cells [61]. IL-10 is responsible
for various functions. It shifts the Th1/Th2 balance by downregulating the Th1 responses and
by suppression of proinflammatory cytokines [62]. Several studies have shown that serum IL-
10 levels are significantly lower in IBD patients than in normal controls, suggesting that altered
IL-10 levels may be involved in the pathogenesis of IBD and may be an IBD biomarker. IL-10 is
capable of depressing the activated immune system. It has been reported that IL-10 knockout
mice develop colitis when they are kept in unsterile environment [63], and the inflammation is
reduced after administration of IL-10 in vivo and in vitro models [64]. Moreover, the produc-
tion of IL-10 has been found to be impaired in severe cases of IBD [65, 66].
IL-10 suppresses CD4+ T helper, Th1, clones (which secrete IL-2, interferon-γ, and TNF-α) and
promotes the immunomodulatory T helper, Th2, clones (which secrete IL-4, IL-10, and IL-13).
The secretion of cytokines is responsible for regulating the balance between Th1 and Th2 cells
which is critical for immunoregulation. In case of reduced capacity of T cells to produce IL-10
in response to a stimulus, Th1 responses continue with the breakdown of peripheral tolerance
and are potential to develop autoimmunity [67].
IL-10 is a multifunctional cytokine mainly produced by immune cells, such as T cells, mono-
cytes, appropriately stimulated macrophages, some subsets of dendritic cells (DCs), and B cells
[68]. Non-immune cell sources of IL-10 also exist, including keratinocytes, epithelial cells, and
some tumor cells [69, 70]. The human IL-10 gene is located on chromosome 1q32.1 and
contains five exons. Recently, IL-10 has been identified as an important player in the develop-
ment of immunological and inflammatory responses involving in the pathogenesis of various
diseases including IBD [71–73].
Several single nucleotide polymorphisms (SNPs) have been reported in the proximal and distal
regions of the IL-10 gene, out of which three promoter polymorphisms (rs18000896-1082A/G,
rs1800871-819T/C, and rs1800872-592A/C) are involved in IL-10 transcription rate and directly
affect its production level and expression [74–77]. The -1082G, -819C, and -592C (GCC) alleles
have been associated with elevated levels of IL-10 production [78], while ACC and ATA
haplotypes show intermediate and low IL-10 gene transcription, respectively [79]. These IL-10
gene polymorphisms are reported to be associated with susceptibility/development to various
inflammatory disorders [40, 80–82]. However, data are limited and inconsistent and therefore
do not allow drawing unequivocal conclusions.
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Studies on the IL-10 promoter polymorphisms and IBD susceptibility have also been inconsis-
tent [71, 83–89]. Some studies have found an associations between IL-10 polymorphism and
IBD [71, 86, 87, 90], whereas other studies were unable to find any association between IBD
and the IL-10 promoter polymorphisms [83, 84, 88, 91]. In this study, we evaluated the associ-
ation of five polymorphism in IL-10, TNF-α, and TNF-β genes with susceptibility risk of IBD in
Saudi patients.
2. Methods
2.1. Subjects
Study groups consisted of 379 Saudi subjects including 179 IBD patients and 200 age- and sex-
matched healthy controls visiting Gastroenterology Clinic of Prince Sultan Military Medical
City (PSMMC), Riyadh. IBD patients included 20 cases of familial forms and 159 cases of
sporadic forms. Of these patients, 95 were diagnosed to suffer with CD (57 men, 38 women)
aged 17–65 years (mean age 32 years), while 84 patients with UC (34 men, 50 women) aged
22–68 years (mean age 34 years). Control group consisted of 120 men and 80 women matched
for age and ethnicity (Saudi). Control subjects were screened for any history of IBD, diabetes,
rheumatoid arthritis, systemic lupus erythematosus, or other autoimmune/inflammatory dis-
eases and excluded if found positive. The diagnoses of CD and UC were based on conven-
tional endoscopic, radiological, and histological criteria [92]. Demographic and clinical data
were collected and used for exclusion and inclusion as described elsewhere [93]. This study
was approved by the research and ethical committee of PSMMC, and written informed con-
sent was obtained from all subjects to participate in this study.
2.2. Polymerase chain reaction (PCR) amplification
Venus blood (3 ml) was collected from all the participants, and genomic DNA was extracted
using a commercially available kit (Qiagen, CA, USA). To detect polymorphisms at position -
308 and intron 1 +252 of the TNF-α and TNF-β genes, respectively, and at position -592, -819
and -1082 of IL-10 gene, the amplification of TNF-α, TNF-β, and IL-10 genes was performed
using an amplification refractory mutation systems PCR methodology described elsewhere
[39, 93]. PCR amplification was carried out in PuReTaq Ready-to-Go PCR Beads (GE
Healthcare, Buckinghamshire, UK) as described earlier [82]. The allele and genotype frequen-
cies of all 5 polymorphisms were evaluated in IBD patients and controls. Hardy-Weinberg
equilibrium was determined using Hardy-Weinberg Equilibrium Calculator for 2 Alleles.
(http//www.had2know.com/academics/hardy-weinberg-equilibrium calculator-2alleles.html)
2.3. Statistical analysis
The difference between the frequency distribution of various alleles and genotypes in patients
and controls was analyzed by Fisher’s exact test using the CalcFisher software (http://www.
jstatsoft.org/v08/i21/paper), and the P-values ≤0.05 were considered as significant. The odd
ratio interpreted as relative risk (RR) indicated the strength of the association of disease with
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respect to a particular allele/genotype and was calculated according to the method of Woolf as
outlined by Schallreuter et al. [94]. The RR was calculated using the following formula only for
those alleles and genotype, which were increased or decreased in IBD patients as compared to
normal Saudis.
RR ¼
a·d
b · c
(1)
where “a” indicates number of patients expressing the allele or genotype, “b” number of
patients without allele or genotype expression, “c” number of controls expressing the allele or
genotype, and “d” number of controls without allele or genotype expression.
The etiologic fraction (EF) is the hypothetical genetic component of the disease. Values >0.00–
0.99 are significant. EF is calculated for positive associations where value of RR is >1 using the
following formula [95]:
EF ¼
ðRR 1Þf
RR
,where f ¼
a
aþ c
(2)
Preventive fraction (PF) shows the hypothetical protective effect of one allele/genotype for a
disease. PF is calculated for negative associations where RR is <1 using following formula [95].
Values >0.00–0.99 indicate the protective effect of an allele/genotype against the manifestation
of disease.
PF ¼
ð1 RRÞf
RRð1 fÞ þ f
,where f ¼
a
aþ c
(3)
3. Results
The representative gel pictures of amplification of different genotypes for TNF-α (-308G/A)
and TNF-β (+252A/G) are shown in Figures 1 and 2.
Allelic frequencies and genotype distributions of TNF-α (-308G/A) and TNF-β (+252A/G) poly-
morphisms were different in patients and controls. The allele frequencies of both patients and
Figure 1. Shows the amplification of TNF-α (-308G/A) alleles (G and A). Lane M: 100-bp DNA marker, lanes 1 and 3:
amplification of allele G, lanes 2 and 6: amplification of allele A, 184-bp band for target DNA, 329-bp band for internal
control.
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controls were in Hardy-Weinberg equilibrium. The frequencies of genotype GA and allele A
were significantly higher, while those of genotypes (GG and AA) and allele A of TNF-α (-
308G/A) were lower in IBD patients as compared to controls (Table 1). Allele A and genotype
GA were susceptible to the IBD (P < 0.001), while allele G and genotype GG were protective
against IBD (P < 0.001) in Saudi patients.
Because of the fact that two forms of IBD are characterized by different clinical pictures, it is
reasonable to perform genetic association studies on homogenous group of patients; therefore,
the genotyping results were stratified into UC and CD. However, similar association with
TNF-α (-308G/A) polymorphism was noticed in the two groups. The genotype GA and allele
A were significantly associated with CD and UC susceptibility in our population (Table 2
and Figure 1). Allele A and genotype GAwere susceptible to the UC and CD (Ps < 0.01), while
allele G and genotype GG were protective (Ps < 0.01) in Saudi patients with UC and CD.
The association of TNF-α (-308G/A) polymorphism with UC, CD, or IBD in various ethnic
populations worldwide has been summarized in Table 3. The association is not consistent, and
Figure 2. Shows the amplification of TNF-β (+252A/G) alleles (A and G). Lane M: 100-bp DNA marker, lanes 1, 3, and 5:
amplification of allele G, lanes 4 and 6: amplification of allele A, 94-bp band for target DNA, 240-bp band for internal
control.
Genotype/allele IBD (n = 179) Control (n = 200) P-value RR EF*/PF
n % n %
GG 5 2.79 110 55 0.00001♣ 0.235 0.123
GA 173 96.65 76 38 0.0001♣ 47.044 0.080*
AA 1 0.56 14 7 0.0009♣ 0.075 0.449
G-allele 183 51.12 296 74 0.0001♣ 0.367 0.397
A-allele 175 48.88 104 26 0.0001♣ 2.722 0.396*
EF = Etiologic fraction, PF = preventive fraction.
♣Statistically significant.
*data for EF
Table 1. Genotype and allele frequencies of TNF-α (-308G/A) polymorphism in IBD patients and matched controls.
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ethnic variations are evident in the type or/and degree of association of TNF-α (-308G/A)
polymorphism and IBD, UC, or CD susceptibility/severity or response to therapy.
On the other hand, studies on TNF-β gene polymorphism showed that the frequency of GG at
position +252 of intron 1 was significantly higher in IBD as compared to controls, while the
frequency of GA genotype was also higher in patient group but the difference was not statis-
tically significant. The difference in the distribution of allele A and allele G was also not
statistically significant in IBD and control groups albeit the frequency of mutant allele G is
higher in IBD patients (Table 4).
The stratification of TNF-β gene polymorphism results for IBD patients into UC and CD
showed that the distribution of genotypes GG and GA was different in UC as compared to
controls indicating that the genotype GG is susceptible and GA protective only for UC but not
for CD as almost similar distribution of genotypes and allele frequencies of TNF-β -intron 1
+252 polymorphism was found among the CD and controls (Table 5 and Figure 2).
The frequency distribution of alleles and genotypes of both TNF-α and-β polymorphisms is
not affected by gender or type of IBD (familial or sporadic) (Tables 6 and 7).
The representative gel pictures of amplification of different genotypes for IL-10 G (-1082)A, IL-
10 C (-819)T, and IL-10 C (-592)A are shown in Figures 3–5.
The results of three promoter polymorphism of IL-10 gene are summarized in Tables 8–12. The
genotype GG of IL10 (-1082) was significantly higher (P = 0.02) in IBD patients (15.08%) than
control group (7.50%). Contrarily, the genotype AA was found to be significantly lower (P =
0.02) in IBD patients (9.50%) as compared to controls (17.50%). On the other hand, the hetero-
zygous GA genotype was almost same in patients and controls (P = 0.99) (Table 8).
Upon stratification of genotyping results into CD and UC, we noticed that frequency of genotypes
and alleles of IL-10 G (-1082)A differed significantly between CD patients and controls. Frequen-
cies of genotype GG and allele G were higher in CD patients while those of genotype AA and
allele A lower in CD patients as compared to controls. On the other hand, no significant different
was found in the frequencies of alleles and genotypes between UC and controls (Table 9).
The frequency of -819 CC genotype was 33.52% in the IBD patients compared to 41.50% in
controls, while CT was 38.12% in IBD patients as compared to 48.50% in controls. The fre-
quency of homozygous TT genotype was similar in both IBD and control samples (10.61 vs.
10.00%). The frequencies of all genotypes of IL-10 (819C/T) polymorphism did not differ
Genotype/allele CD (95) n (%) UC (84) n (%) Control (200) n (%)
GG 3 (3.16)* 2 (2.38)* 110 (55)
GA 91 (95.79)* 82 (97.62)* 76 (38)
AA 1 (1.05)* 0 (0.0)* 14 (7)
G-allele 97 (51.05)* 86 (51.19)* 296 (74)
A-allele 93 (48.95)* 82 (48.81)* 104 (26)
*P value <0.05 compared to the frequency in controls.
Table 2. Genotype and allele frequencies of TNF-α (-308G/A) polymorphism in UC and CD patients.
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Ethnicity/population Type of association with IBD Reference
American UC susceptibility [96]
*Asian Associated with UC [59]
*Asian Associated with UC and CD [58]
*Asian Associated with UC susceptibility [97]
Belgian No association with CD treatment [98]
Belgian Associated with CD behavior [99]
Brazilian Associated with severity of CD [60]
Canadian No association with CD [27]
Canadian No association with IBD [100]
*Caucasians Better response to TNF blockers [101]
Czech Associated with IBD [102]
Dutch No association with IBD [103]
English IBD susceptibility [104]
*European No association with UC [97]
*European Associated with UC and CD [58]
German No association with IBD [105]
Han Chinese Association with UC susceptibility [106]
Han Chinese Association with UC susceptibility [57]
Hungarian IBD susceptibility [107]
Indian No association with IBD [108]
Iranian No association with IBD [109]
Iranian No association with IBD [110]
Irish No association with IBD [83]
Israeli No association with granulomas in CD [111]
Italian Associated with therapy [112]
Japanese UC susceptibility [113]
Korean Association with CD susceptibility [114]
Korean Association with CD susceptibility [115]
Mexican-Mestizo UC susceptibility [116]
Portuguese Pathological profiles of CD [117]
Russian UC susceptibility [118]
Saudis IBD susceptibility [93]
Spanish No association with CD [114]
Spanish No association with UC [119]
Turkish No association with IBD susceptibility [120]
Turkish Association with UC susceptibility [121]
*meta–analysis
Table 3. Association of TNF-a 308G/A polymorphism in UC, CD, or IBD in various ethnic populations worldwide.
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Genotype/allele IBD (n = 179) Control (n = 200) P-value RR EF*/PF
n % n %
GG 39 21.79 28 14 0.05♣ 1.711 0.241*
GA 120 67.04 148 74 0.14 0.714 0.151
AA 20 11.17 24 12 0.87 0.922 0.037
G-allele 198 55.31 204 51 0.24 1.189 0.078*
A-allele 160 44.69 196 49 0.24 0.841 0.078
EF = Etiologic fraction, PF = preventive fraction.
♣Statistically significant.
*data for EF
Table 4. Genotype and allele frequencies of TNF-β (+252A/G) polymorphism in IBD patients and matched controls.
Genotype/allele CD (n = 95) n (%) UC (n = 84) n (%) Control (n = 200) n (%)
GG 16 (16.84) 23 (27.38)* 28 (14)
GA 69 (72.63) 51 (60.72)* 148 (74)
AA 10 (10.53) 10 (11.90) 24 (12)
G-allele 101 (53.16) 97 (57.74) 204 (51)
A-allele 89 (46.84) 71 (42.26) 196 (49)
*P value <0.05 compared to the frequency in controls.
Table 5. Genotype and allele frequencies of TNF-β (+252A/G) polymorphism in CD and UC patients.
Genotype/allele Male (n = 89) Female (n = 90) P-value
n % n %
GG 23 25.84 16 17.78 0.209
GA 57 64.05 63 70.00 0.429
AA 9 10.11 11 12.22 0.813
G-allele 103 57.87 95 52.78 0.340
A-allele 75 42.13 85 47.22 0.340
N = number of subjects.
Table 6. Genotype and allele frequencies of TNF-β (+252A/G) polymorphism in IBD male and female patients.
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significantly in patients and control groups. The allelic frequencies were also not different in
patient and control groups (Table 10).
Upon stratification of subjects in to CD and UC, no significant difference was found in
distribution of alleles and genotypes between patients and controls (Table 11).
Genotype/allele Familial (n = 22) Sporadic (n = 157) P-value
n % n %
GG 4 18.18 35 22.29 0.780
GA 15 68.18 105 66.88 1.000
AA 3 13.64 17 10.83 0.717
G-allele 23 52.27 175 55.73 0.746
A-allele 21 47.73 139 44.27 0.746
Table 7. Genotypes and alleles of TNF-β (+252A/G) polymorphism in familial and sporadic IBD patients.
Figure 3. Shows the amplification of IL-10-1082G/A genotypes (GG, GA, and AA). Lane M: 100-bp DNA marker, lanes 1,
5, and 7: amplification of allele G, lanes 2,4, and 6: amplification of allele A, 258-bp band for target DNA, 429-bp band for
internal control.
Figure 4. Shows the amplification of IL-10-819C/T genotypes (CT and CC). Lane M: 100-bp DNA marker, lanes 1, 3, and
5: amplification of allele C, lanes 2 and 6: amplification of allele T, 233-bp band for target DNA, 429-bp band for internal
control.
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Similarly, the frequencies of alleles and genotypes of IL-10(-592C/A) polymorphism were not
significantly different in IBD patient and controls (Table 12).
Upon stratification of subjects into CD and UC, no significant difference was found in distri-
bution of IL-10(-592C/A) alleles and genotypes between patients and controls (Table 13)
Figure 5. Shows the amplification of IL-10-592C/A genotypes (CC, CA, and AA). Lane M: 100-bp DNAmarker, lanes 1, 3,
5, and 7: amplification of allele C, lanes 4, 6, 8, and 10: amplification of allele A, 233-bp band for target DNA, 429-bp band
for internal control.
Genotype/allele IBD (n = 179) Control (n = 200) P-value RR EF*/PF
n % n %
GG 27 15.08 15 7.50 0.02♣ 2.19 0.347*
GA 135 75.42 150 75.00 0.99 1.02 0.009*
AA 17 9.50 35 17.50 0.02♣ 0.49 0.253
G-allele 189 52.79 180 45.00 0.03♣ 1.36 0.135*
A-allele 169 47.21 220 55.00 0.03♣ 0.73 0.138
EF = Etiologic fraction, PF = Preventive fraction.
♣Statistically significant.
*data for EF.
Table 8. Genotype and allele frequencies of (-1082G/A) IL-10 variants in IBD and matched controls.
Genotype/allele CD (95) n (%) UC (84) n (%) Control (200) n (%)
GG 17 (17.90)* 10 (11.90) 15 (7.5)
GA 73 (76.84) 62 (73.81) 150 (75.0)
AA 5 (5.26)* 12 (14.29) 35 (17.50)
G-allele 107 (56.32)* 82 (48.81) 180 (45.0)
A-allele 83 (43.68)* 86 (51.19) 220 (55.0)
*P value <0.05 compared to the frequency in controls.
Table 9. Genotype and allele frequencies of (-1082G/A) IL-10 variants polymorphism in UC and CD patients.
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The association of IL-10 promoter polymorphism with UC, CD, or IBD in various ethnic
population worldwide has been summarized in Table 14. The association is not consis-
tent, and ethnic variations are evident in the type polymorphism and IBD, UC, or CD
susceptibility.
Genotype/allele IBD (n = 179) Control (n = 200) P-value RR EF*/PF
n % n %
CC 60 33.52 83 41.50 0.11 0.91 0.039
CT 100 55.87 97 48.50 0.18 1.34 0.128*
TT 19 10.61 20 10.00 0.86 1.06 0.027*
C-allele 220 61.45 263 65.75 0.22 0.83 0.085
T-allele 138 38.55 137 34.25 0.22 1.20 0.084*
*data for EF
Table 10. Genotype and allele frequencies of (819C/T) IL-10 variants in IBD and matched controls.
Genotype/Allele CD (95) n (%) UC (84) n (%) Control (200) n (%)
CC 31 (32.63) 29 (34.52) 83 (41.50)
CT 53 (55.79) 47 (55.95) 97 (48.50)
TT 11 (11.58) 8 (9.53) 20 (10.00)
C-allele 115 (60.53) 105 (62.5) 263 (65.75)
T-allele 75 (39.47) 63 (37.5) 137 (34.25)
Table 11. Genotype and allele frequencies of (819C/T) IL-10 variants polymorphism in UC and CD patients.
Genotype/allele IBD (n = 179) Control (n = 200) P-value RR EF*/PF
n % n %
CC 60 33.52 83 41.50 0.11 0.91 0.039
CA 100 55.87 97 48.50 0.18 1.34 0.128*
AA 19 10.61 20 10.00 0.86 1.06 0.027*
C-allele 220 61.45 263 65.75 0.22 0.83 0.085
A-allele 138 38.55 137 34.25 0.22 1.20 0.084*
*data for EF
Table 12. Genotype and allele frequencies of (-592C/A) IL-10 variants in IBD and matched controls.
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Genotype/allele CD (95) n (%) UC (84) n (%) Control (200) n (%)
CC 31 (32.63) 29 (34.52) 83 (41.50)
CA 53 (55.79) 47 (55.95) 97 (48.50)
AA 11 (11.58) 8 (9.53) 20 (10.00)
C-allele 115 (60.53) 105 (62.5) 263 (65.75)
T-allele 75 (39.47) 63 (37.5) 137 (34.25)
Table 13. Genotype and allele frequencies of (592C/A) IL-10 variants polymorphism in UC and CD patients.
Ethnicity/population IL-10 polymorphism Type of association with IBD Reference
Australian 1082 G/A, 592 C/A CD susceptibility [84]
Canadian 1082 G/A, 819 C/T, 592 C/A No association with IBD [100]
Canadian 819 C/T Associated with CD [87]
*Caucasian 1082 G/A, 819 C/T Associated with IBD susceptibility [89]
*Caucasian 592 C/A No association with IBD [89]
Caucasian 1082 G/A Associated with IBD [38]
*Mixed 819 C/T, 519 C/A Associated with UC [88]
*Mixed 1082 G/A No association with CD or UC [88]
Mixed 1082 G/A, 819 C/T, 592 C/A Associated with CD phenotype [73]
*Mixed 1082 G/A Associated with CD, No association with UC [122]
New Zealand population 1082 G/A Associated with CD, [72]
Indian 1082 G/A, 819 C/T, 592 C/A No association with IBD [123]
Mexican 1082 G/A, 592 C/A Associated with IBD susceptibility [90]
Danish 1082 G/A, 819 C/T, 592 C/A No association with IBD [124]
Tunisian Promoter polymorphism Associated with CD [125]
Turkish 1082 G/A No association with IBD [120]
Spanish 1082 G/A, 819 C/T, 592 C/A No association with UC or CD [126]
Spanish 1082 G/A Associated with CD [71]
Hungarian 1082 G/A No association with CD [127]
Korean Promoter polymorphism No association with IBD [114]
German 1082 G/A, 592 C/A No association with IBD [91]
Italian 1082 G/A Associated with UC [86]
Italian 819 C/T No association with UC [86]
*Meta-analysis.
Table 14. Association of IL-10 promoter polymorphisms in UC, CD, or IBD in various ethnic populations worldwide.
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4. Discussion
TNF-α being a key cytokine in the inflammatory response of IBD plays an important role in the
digestive and systemic manifestations of the disease. Available literature on the TNF-α (-308G/
A) polymorphism shows its importance in the pathogenesis of CD and UC [58–60]. From the
outgoing results, it is clear that allele A and genotype GA of TNF-α (-308G/A) polymorphism
are associated with IBD susceptibility in Saudi population. Our results are in accordance with
the earlier reports from other populations. This polymorphism has been shown to affect the
UC and CD susceptibility in Asians and Europeans. The allele A of TNF-α (-308G/A) is
associated with UC susceptibility in Japanese and Han Chinese patients [57, 106, 113]. The
genotype GA is a risk factor for UC in Asians, whereas homozygous genotype AA is risk for
both UC and CD in European patients [58]. A meta-analysis besides supporting the association
of TNF-α (308G/A) polymorphism with IBD in Asians suggested that genetic polymorphisms
vary in Asians from Caucasians [59].
On the other hand, some reports support the association of TNF-α (-308G/A) polymorphism
with the severity of IBD. TNF-α (-308G/A) polymorphism is reported to be significantly
associated with the severity of CD and/or UC in Irish [83], Czech [102], Italian [112], Caucasian
patients from New Zealand [128], and Brazilian patients [60]. However, it is not clear whether
it is directly involved in pathophysiology of IBD or serve merely as markers in Linkage
disequilibrium with susceptibility genes [83].
Moreover, the carriers of allele A are at greater risk of pancolitis and more likely to require
bowel resection in UC and CD [102, 112]. The CD patients with allele A were reported to be
more resistant to steroids compared with non-carriers. The CRP levels in UC and CD patients
carrying allele A were found to be higher and reported to modify the disease phenotype,
influence its activity, and lead to a more intense inflammatory response [112].
The increased inflammation, higher levels of C-reactive protein (CRP), TNF-α, and interleukin-
1ß have been associated with the A-containing genotypes of TNF-α (-308G/A) polymorphism
in the active phase of IBD [98, 99, 107, 129]. The higher frequency of allele A of TNF-α (308G/A)
was found in anti-neutrophil cytoplasmic antibodies (ANCA)-positive than ANCA-negative
IBD patients, which may have influences on the susceptibility IBD or the behavior of IBD [114].
On the other hand, homozygous genotype AA of TNF-α (-308) has been associated with
susceptibility to CD in Portuguese patients, and it has been suggested that TNF-α (-308G/A)
polymorphism is responsible for displaying distinct clinicopathological profiles in Portuguese
CD patients [117].
However, contrary reports are also available in the literature. The lower frequency of allele A
of TNF-α (-308G/A) has been reported in North European Caucasian and Korean patients with
CD or UC as compared to healthy controls [103]. Although the frequency of allele G was
reported to be slightly higher in Iranian Azeri Turkish IBD patients, it did not reach statistical
significance [110]. Further, no association of TNF-α(-308G/A) polymorphism with IBD suscep-
tibility was found in Australian [82], Brazilian [60, 130], Canadian [100], Chinese [106, 131],
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Czech [132], French [133], Indian [108], Korean [115], Newfoundland [27], Spanish [126], and
Turkish [120] populations. The reason for these differences in the TNF-α genetic associations
with IBD etiology might be the variations in sample size, genotyping methods, and/or ethnic-
ity itself as frequencies of alleles and genotypes of TNF-α (-308G/A) also vary in different
ethnic healthy populations worldwide [39] (Table 3).
Our genotyping results for TNF-β (+252A/G) polymorphism showed that genotype GG was
significantly associated with IBD susceptibility. Our results also indicated that genotype GA
was slightly lower in IBD patient than the controls, but the difference did not reach statistical
significance. However, when the results were stratified into CD and UC, it became evident
that this polymorphism was associated only with UC but not with CD in Saudi population
(Table 4, Figure 2). In contrast, some earlier reports suggested that the TNF-β (+252) poly-
morphism is not associated with CD or UC in Chinese, French, Korean, and Spanish patients
[57, 106, 115, 119, 133]. It is possible that the TNF-β (+252A/G) polymorphism may be
indirectly associated with IBD as it has been suggested to influence the expression/produc-
tion of TNF-α [42].
Muro et al. [134] reported that the inflammatory response in IBD is effected by the changes in
TNF-α and TNF-β levels and IBD patients are commonly treated with TNF-α inhibitors.
Moreover, TNF-α gene polymorphisms are reported to affect the gene expression level of
TNF-α, and a particular TNF-α genotype may influence the response of IBD patients treated
with TNF-α inhibitors as mutated allele A of TNF-α(-308) and allele G of TNF-β(+252) poly-
morphisms have been associated with greater TNF-α transcription [35, 36, 42, 135].
Our study on Saudi IBD patients suggested a significant association between allele and geno-
type frequency of TNF-α (-308G/A) and TNF-β (+252A/G) polymorphisms and IBD suscepti-
bility in Saudi population. It is evident from outgoing discussion that ethnicity plays a very
important role in genetic association of TNF-α and TNF-β polymorphism with IBD. It is also
inferred that the both the polymorphism may have synergistic effect on the susceptibility and
may work in tandem to influence the etiology of IBD in Saudi population. The outcome of
present study will not only help in the prognosis of IBD in Saudi population but also provide
guideline for the treatment with anti-TNF therapy as individuals with different genotypes of
TNF-α (-308G/A) respond differently to anti-TNF-α treatment [136, 137]. However, further
studies are required involving other ethnic populations to strengthen these findings.
The genotyping results for IL-10-1082 G/A polymorphism indicated that genotype -1082GG
and allele G are susceptible to IBD (RR = 2.19, EF = 0.347, RR = 1.36, EF = 0.135, respectively),
while genotype AA and allele A are resistant to IBD (RR = 0.49, PF = 0.0.253, RR = 0.73, PF =
0.138, respectively). Upon stratification of genotyping results into CD and UC, we noticed that
genotype GG and allele G of -1082 G/A polymorphism were associated with CD susceptibility,
while genotype AA and allele A might be protective for CD. On the other hand, no significant
association was found either with alleles or genotypes of -1082 G/A polymorphism and UC in
Saudi patients. These results are in accordance with the various reports, which also indicted an
association of IL-10-1082G/A polymorphism susceptibility to IBD [89, 122]. A meta-analysis
including 18 case-control studies provided evidence for the association between IL-10-1082G/
A polymorphism and susceptibility of CD [122]. Another met-analysis including 15 studies
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demonstrated clear association between the IL-10-1082G/A polymorphisms and the risk of IBD
[89]. The allele G of -1082G/A polymorphism has been associated with the IBD, and higher
serum levels of IL-10 concentration have been reported in IBD patients than in the controls [72,
90]. Earlier studies with CD patients also indicated that IL-10-1082 G/A polymorphisms con-
tribute to susceptibility to CD [71] and -1082G allele was significantly increased in patients
with CD than controls [73] while A allele of the IL-10-1082G/Awas associated with decreased
IL-10 production in CD patients and controls [78].
Contrary to these, some studies reported that there are no significant differences in the allele
and genotype frequencies of the IL-10-1082G/A polymorphism between IBD patients and
controls in various populations [88, 91, 120]. Klein et al. [91] reported that IL-10-1082G/A
polymorphism is not demonstrably involved in the predisposition of IBD in German cohort.
Similarly, no association between Turkish IBD patients and IL-10-1082G/Awas found [120]. A
meta-analysis by Zou et al. [88] observed that IL-10-1082G/A polymorphism is not associated
with IBD. These data provide evidence that the effect of IL-10 gene polymorphisms on cyto-
kine production differs in CD, UC patients, and controls in various populations.
Further, our results indicated that IL-10-1082G/A polymorphism is not associated with UC
susceptibility in Saudi patients. These are in accordance with earlier reports indicating no
association of IL-10-1082G/A polymorphisms with susceptibility of UC [88, 122]. Mendoza
et al. [138] reported that IL-1082G allele is not associated with the phenotype of UC patients
in Madrid’s Spanish population.
On the other hand, IL-10-1082 G/A polymorphism has been reported to influence susceptibility
to UC [38, 86, 126]. A gender effect has been reported, with women of AG/AA genotypes of IL-
10-1082 G/A, having a higher risk of developing UC at a younger age and is related to the
lower IL-10 production associated with the -1082A allele and to the IL10 downregulating effect
of estrogens [86]. A mild influence of -1082 G allele in UC appearance has also been reported
by Castro-Santos et al. [126]. In a stratified analysis, a highly significant association between
the -1082 AA genotype and the steroid dependency was observed in IBD, and it was suggested
that carriage of the -1082 AA genotype (low producer) is a relevant risk factor for developing
steroid-dependent IBD. Tagore et al. [38] suggested that individuals genetically predisposed to
produce less IL-10 are at a higher risk of developing IBD, and the frequency of the high IL-10
producer allele (-1082 G) is decreased in the whole IBD group and in the UC patients com-
pared with normal.
The two other polymorphisms of IL-10 gene (IL-10-819C/T and IL-10-592C/A) are not associ-
ated with the susceptibility of IBD as the frequency distribution of genotypes and alleles of
these two polymorphisms did not differ significantly between controls and IBD patient
groups. The stratification of our results in to CD and UC patients also indicated that IL-10-
819C/T and IL-10-592C/A polymorphisms are associated with neither with CD nor UC suscep-
tibility in our patients. Similarly, Castro-Santos et al. [126] did not find any association between
IL-10 (-812 C/T and -592 C/A) polymorphisms and UC or CD susceptibility. A recent meta-
analysis demonstrated no significant association between the -592C/A polymorphism and IBD,
CD, or UC, but a clear association with IL-10-819C/T polymorphism [89], while several other
report showed that these polymorphisms are associated with IBD risk [72, 87, 88, 90, 139].
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These differences in the association of IL-10-819C/T and IL-10-592C/A polymorphisms with
CD or UC can be attributed to ethnic variations.
The exact mechanism by which IL-10 affects the susceptibility/pathogenesis of IBD is far from
clear. It participates in the regulation of the immune response at several levels [69]. IL-10
regulates the inflammatory response, by inhibiting proinflammatory Th1 cytokines production
[140].
IL-10 cytokine downregulates the expression of major histocompatibility complex (MHC) of
class I and II molecules [141, 142]. It also has potent stimulatory effects on B lymphocytes,
resulting in increased production of immunoglobulin and DNA replication [141]. The
immune-stimulating effects of IL-10 have also been reported. IL-10 is shown to induce acti-
vated B cells to secrete large amounts of IgG, IgA, and IgM and in combination with IL-4
which results in the secretion of four immunoglobulin isotypes. The increased levels of IL-10
play a role in the amplification of humoral responses in some diseases [141].
Sanchez-Munoz et al. [143] suggested that the intestinal inflammation in IBD is controlled by
a complex interplay of innate and adaptive immune mechanisms. Cytokines determine T-cell
differentiation of Th1, Th2, T regulatory, and Th17 cells in IBD, and cytokines levels regulate
the development, recurrence, and exacerbation of the inflammatory process in IBD. The
dysregulation of T cells, or an over-production of effector T cells, results in the development
and exacerbation of IBD [144]. Thus, the antigen-presenting cells (APCs), Th1, Th2, T regu-
latory cells, and Th17 and their cytokine products play an important role in the etiology of
IBD [8]. These cellular interactions are modulated by pro- or anti-inflammatory cytokines
(such as TNF-α, INF-γ, IL-1, IL-6, IL-4, IL-5, IL10, TGF-β, IL-13, IL-12, IL-18, IL-23) [145].
Although many common responses in IBD are mediated by cytokines, how cytokines deter-
mine the nature of the immune response in IBD may be quite different among different IBD
forms [146].
A highly significant increase in IL-10 mRNA levels in T lymphocytes and in IL-10-positive cells
in the colons of UC patients has been reported by Melgar et al. [147]. Moreover, IL-10 produc-
tion by regulatory T cells has also been implicated as important factor in IBD [148]. Another
regulatory B cells subtype called Bregs may also take part in UC etiology by producing IL-10
[149]. The significance of IL-10 produced by B cells has been indicated in IBD patients and
animal models also [150, 151]. The Bregs can be responsible for the suppression and/or recov-
ery from acquired immune-mediated inflammations by IL-10 and TGF-β1 in IBD [143, 149].
However, the exact mechanism is still far from clear and needs to be investigated.
5. Conclusion
Our study dealing with the five polymorphisms of proinflammatory and anti-inflammatory
cytokine genes in Saudi IBD patients clearly indicates that the TNF-α (-308G/A), TNF-β
(+252A/G), and IL-10 (-1082 G/A) polymorphisms are associated significantly with the risk of
IBD susceptibility while other two, IL-10-819C/T and IL-10-592C/A, polymorphisms are not
associated with IBD in Saudi population. However, due to several limitations in the present
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study, it is suggested that well-designed epidemiological as well as genetic association studies
with large sample size among different ethnicities should be performed in order to have better
understanding of this relationship.
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